Study finds intraocular pressure improved when switched to XALATAN from other monotherapy
Fort Lauderdale, Florida (May 8, 2002) Switching to XALATAN (latanoprost ophthalmic solution) once daily from monotherapy with other medications, including prostaglandin derivatives, for open angle glaucoma or ocular hypertension resulted in improved or maintained intraocular pressure (IOP) control, according to new data presented at the Association for Research in Vision and Ophthalmology (ARVO...Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with XALATAN® (latanoprost ophthalmic solution) presented no new safety concerns and effectively lowered intra-ocular pressure (IOP) in patients with open-angle glaucoma (OAG). XALATAN is the only p...